Osteochondritis Dissecans Clinical Trials

Find Osteochondritis Dissecans Clinical Trials Near You

Multicenter Prospective Randomized Study of MaioRegenTM Prime vs. Debridement (Surgical Standard of Care (SSOC)) for the Treatment of Osteochondral Lesion of the Knee Joint - OSTEOCONFIRM Study

Status: Recruiting
Location: See all (10) locations...
Intervention Type: Device, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The present study aims to compare the efficacy and the safety of MaioRegen Prime to Debridement (SSOC) in patients with deep osteochondral lesions of the knee joint. The foreseen population involves patients with osteochondral lesions with different etiology, dimension, shape, and location. The evaluation will be performed through clinical, subjective and objective assessments.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: f
View:

• Informed consent prior to any study-related procedures;

• Male or female patients aged between 18 and 60 years (inclusive);

• Body Mass Index (BMI) ≤ 35;

• Up to 3 treatable osteochondral lesions localized in femoral condyles and/or trochlea (the patient might have other lesion in other parts of the joint, but they should not be more severe than ICRS Grade II lesions as determined by baseline MRI);

• Knee osteochondral lesion(s) (Grade IVa and IVb according to ICRS Classification) or not re-fixable knee Osteochondritis Dissecans lesions as determined by baseline MRI;

• Lesions with an overall treatable area 1-7 cm2 (as determined by baseline MRI). In case of multiple lesions (maximum 3 lesions) in the same knee compartment a minimum distance of 3 mm is required);

• IKDC Subjective score at baseline (pre-op evaluation) is less than 70;

• Non-responsive to physical therapy for at least 6 weeks;

• Patients physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits.

Locations
United States
California
Grossmont Orthopaedic Medical Group
NOT_YET_RECRUITING
La Mesa
Colorado
Steamboat Orthopaedic & Spine Institute
RECRUITING
Steamboat Springs
Illinois
Genesis Orthopedics & Sports Medicine
RECRUITING
Oak Brook
Michigan
University of Michigan Med school
RECRUITING
Ann Arbor
Ohio
University of Cincinnati Medical Center
RECRUITING
Cincinnati
Ohio State University
RECRUITING
Columbus
Oregon
Oregon Health & Science University in Portland
RECRUITING
Portland
Tennessee
Clinical Research Solutions
RECRUITING
Jackson
Texas
North Texas Medical Research Institute
RECRUITING
Rockwall
Other Locations
Italy
IRCCS Rizzoli Orthopedic Institute
RECRUITING
Bologna
Contact Information
Primary
Simal Trikam, Clinical Trial Manager
strikam@mcra.com
+44 7889983972
Backup
Roberta Miale, MEng
roberta.miale@finceramica.it
+39 0546645438
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2031-04-30
Participants
Target number of participants: 400
Treatments
Experimental: MaioRegen Prime
Medical Device: MaioRegen Prime implant
Active_comparator: Surgical Standard of Care (SSOC)
Debridement
Sponsors
Leads: Fin-Ceramica Faenza Spa

This content was sourced from clinicaltrials.gov

Similar Clinical Trials